Dispelling the Myths: Point-Counterpoint Debate on European and US Treatment Guidelines for Bipolar Disorder

Log in for full access to this session if you are registered.

Registration Options

Registration closed.

Session Summary

Bipolar disorder affects approximately 1% of the worldwide population. Several pharmacologic options are available to treat this condition and treatment guidelines are available to direct treatment. Common treatment guidelines in the United States include the American Psychiatric Association guidelines, the Expert Consensus Guidelines, and the Texas Implementation of Medical Algorithms for Bipolar Disorder treatment algorithm, while European guidelines include the European Collegeof Neuropsychopharmacology (ECNP) Consensus Statement on Bipolar Disorder and the National Institute for Health and Clinical Excellence (NICE) guidelines.

Although similarities exist between the U.S. And European guidelines, several key differences are also apparent.  or example, carbamazepine is considered a second-line option for the treatment of mania or hypomania in the US, while the NICE guidelines advise against the routine use of carbamazepine in Europe. In the US, lamotrigine is recommended as a potential first-line option for treatment of acute bipolar depression, while the NICE guidelines state that lamotrigine should not be used as a single, first-line agent. Finally, the US guidelines support that use of risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole as potential first or second-line options for the treatment of manic/hypomanic episodes while the NICE guidelines only routinely recommend the use of risperidone, olanzapine, and quetiapine. In this session, evidence supporting each country's recommendations will be presented and debated in a point-counterpoint format.

Registrant Resources

Sorry, but you are not an authorized user. Please register for the course at the top of this page.

Faculty Information

Charles L. Bowden, MD
Heinz C.R. Grunze, MD,PHD

View biographical information and disclosures

Learning Objectives

  1. Describe and compare current European and US guidelines for the treatment of bipolar disorder, noting key differences.
  2. Examine the literature on the efficacy of lamotrigine for the acute and maintenance treatment of bipolar disorder.
  3. Review the role of antidepressants in the treatment of bipolar depression. 
  4. Differentiate the effectiveness of the available second-generation antipsychotics in the treatment of bipolar disorder.
  5. Analyze the current data available regarding the efficacy of carbamazepine for the acute and maintenance treatment of bipolar disorder.

Continuing Education Credit

Activity Dates: 04/21/2009 - 04/21/2012
ACPE Contact Hours: 2.0
ACPE Number: 0284-0000-09-009-H01-P
Nursing Credit Reminder: Note that ACPE and ACCME credit is accepted for certification renewal.

Course Requirements

This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.

Participants in this course must complete an examination and achieve a score of 60% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.

Target Audience

If you are a pharmacist, nurse practitioner or other healthcare professional involved in the medication therapy management of psychiatric and/or neurological patients, we invite you to participate in this online course.

Grant Support

This programming was supported in part by grants from Bristol-Myers Squibb, Forest Laboratories, Inc., Lilly, Schering-Plough, Cyberonics, and Shire.